Skip to main content

Table 3 Comparison of common clinical characteristics according to the 10 marker gene expression-based risk groups

From: An improved advanced fragment analysis-based classification and risk stratification of pediatric acute lymphoblastic leukemia

Variable/category

Gene expression-based risk group

χ2

P value

GR group n (%)

PR group n (%)

Total number of patients

362 (95.8)

16 (4.2)

  

Age (year)

 ≥ 10

41 (11.3)

2 (12.5)

6.75

0.031

 1–10

316 (87.3)

12 (75.0)

  

 < 1

5 (1.4)

2 (12.5)

  

Gender

 Male

229 (63.3)

9 (56.2)

0.32

0.570

 Female

133 (36.7)

7 (43.8)

  

WBC (× 109/l)

 ≥ 50 × 109/l

72 (19.9)

12 (75.0)

23.83

< 0.001

 < 50 × 109/l

290 (80.1)

4 (25.0)

  

Immunophenotype

 T-ALL

29 (8.0)

7 (43.8)

18.76

< 0.001

 B-ALL

333 (92.0)

9 (56.2)

  

Chromosome abnormalities in B-ALL

 BCR-ABL1

20 (6.0)

6 (66.7)

31.22

< 0.001

 E2A-PBX1

27 (8.1)

0

  

 TEL-AML1

109 (32.7)

0

  

 MLL rearrangements

8 (2.4)

2 (22.2)

  

 Hyperdiploid > 50

107 (32.1)

0

  

 Other B-ALL

62 (18.6)

1 (11.1)

  

Prednisone response

 Good

351 (97.0)

11 (68.8)

23.53

< 0.001

 Poor

11 (3.0)

5 (31.2)

  

MRD at day 33

 Positive

12 (3.6)

3 (27.3)

9.04

0.003

 Negative

317 (96.4)

8 (72.7)

 Not evaluated

33

5

MRD at day 78

 Positive

7 (2.2)

2 (22.2)

6.69

0.010

 Negative

311 (97.8)

7 (77.8)

 Not evaluated

44

7

Clinical risk group

 Standard risk

87 (24.0)

0

30.83

< 0.001

 Intermediate risk

230 (63.5)

4 (25.0)

 High risk

45 (12.4)

12 (75.0)

Outcome

 Eventa

36 (9.9)

13 (81.3)

62.88

< 0.001

 Remission

326 (90.1)

3 (18.7)

  
  1. aEvent: ALL relapse, second malignant neoplasms (SMNs) or death